Cargando…
Cisplatin Resistance in Osteosarcoma: In vitro Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments
Treatment of high-grade osteosarcoma, the most common malignant tumor of bone, is largely based on administration of cisplatin and other DNA damaging drugs. Altered DNA repair mechanisms may thus significantly impact on either response or resistance to chemotherapy. In this study, by using a panel o...
Autores principales: | Fanelli, Marilù, Tavanti, Elisa, Patrizio, Maria Pia, Vella, Serena, Fernandez-Ramos, Amira, Magagnoli, Federica, Luppi, Silvia, Hattinger, Claudia Maria, Serra, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077033/ https://www.ncbi.nlm.nih.gov/pubmed/32211337 http://dx.doi.org/10.3389/fonc.2020.00331 |
Ejemplares similares
-
Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells
por: Vella, Serena, et al.
Publicado: (2016) -
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma
por: Hattinger, Claudia M., et al.
Publicado: (2016) -
Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact
por: Hattinger, Claudia Maria, et al.
Publicado: (2020) -
Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
por: Tavanti, E, et al.
Publicado: (2013) -
Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing
por: Hattinger, Claudia Maria, et al.
Publicado: (2022)